Welcome to our dedicated page for Arbutus Biopharm news (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharm stock.
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company focused on infectious disease, with a particular emphasis on chronic hepatitis B virus (cHBV) infection. The ABUS news feed highlights company announcements on clinical data, corporate strategy and intellectual property developments that shape the outlook for its pipeline and technology.
Investors and observers following ABUS news can find regular updates on imdusiran (AB-729), Arbutus’ RNAi therapeutic designed to reduce hepatitis B viral proteins and antigens including HBsAg. News items include results from Phase 1 and Phase 2a trials, such as reports of patients achieving what the company describes as functional cure, analyses of HBsAg and HBV DNA reductions, and presentations at major liver disease conferences including the European Association for the Study of the Liver (EASL) Congress and the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting.
The ABUS news stream also covers developments related to AB-101, the company’s oral PD-L1 inhibitor candidate. Releases describe safety, tolerability and pharmacodynamic findings from the ongoing Phase 1a/1b trial in healthy volunteers and cHBV patients, including data on PD-L1 receptor occupancy and the absence of AB-101-related serious adverse events reported to date.
Another recurring theme in Arbutus news is its LNP intellectual property. Joint announcements with Genevant Sciences and company updates detail U.S. and international patent infringement actions against Moderna and Pfizer/BioNTech concerning the use of LNP technology in COVID-19 vaccines. Corporate news also includes board and executive changes, restructuring actions, and strategic decisions such as reacquiring Greater China rights to imdusiran and forming a Scientific Advisory Board of cHBV experts.
For those tracking ABUS stock and the company’s progress in hepatitis B and LNP technology, this news page provides a centralized view of clinical milestones, litigation updates and corporate developments as disclosed by Arbutus in its press releases.
Arbutus Biopharma Corporation (Nasdaq: ABUS) has received regulatory approval to start a Phase 1a/1b clinical trial for AB-836, its oral capsid inhibitor targeting chronic hepatitis B virus (HBV) infection. The trial initiation is a significant milestone toward potential combinations with AB-729. Pre-clinical studies suggest that AB-836 may offer improved efficacy and safety compared to earlier capsid inhibitors. This candidate has demonstrated activity against resistant HBV variants, highlighting its potential in a large patient population suffering from chronic HBV, estimated at over 250 million globally.
Arbutus Biopharma Corporation (Nasdaq: ABUS) reported robust clinical progress for its lead compound, AB-729, an RNAi agent targeting chronic hepatitis B (HBV). The latest data show significant declines in hepatitis B surface antigen (HBsAg) levels, with favorable safety profiles. Upcoming clinical trials include Phase 2 combinations of AB-729 with core inhibitors. Financially, the company ended 2020 with $123.3 million in cash, a reduction in net loss to $75.9 million, and reduced expenses, projecting a cash runway through Q3 2022.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that CEO William Collier will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation focuses on the company's efforts to develop a cure for chronic hepatitis B virus (HBV) infections and therapies for coronaviruses, including COVID-19. Interested parties can access the webcast on Arbutus' website starting at 7:00 am (EST) on March 9, with an archived replay available afterward.
Assembly Biosciences and Arbutus Biopharma have initiated a Phase 2 clinical trial to evaluate the combination of Assembly's vebicorvir (VBR) and Arbutus’ AB-729 with standard NrtI therapy for chronic hepatitis B Virus (HBV) infection. The trial aims to enroll around 60 patients and assess the safety and antiviral activity of the treatments over 48 weeks. Both companies believe this multi-drug approach is essential for achieving a durable functional cure for HBV, addressing the significant unmet need in HBV therapies.
Arbutus Biopharma Corporation (Nasdaq: ABUS) will announce its fourth quarter and year-end 2020 financial results on March 4, 2021. The press release will be available at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET. The company focuses on developing a cure for chronic hepatitis B virus (HBV) and therapies for coronaviruses, including COVID-19. Live access to the conference call will be available via the company's investor website.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its 2021 objectives and financial update, focusing on its hepatitis B research and development pipeline. The lead asset, AB-729, shows promising Phase 1a/b clinical trial results, with plans for Phase 2a trials this year. Additionally, AB-836 is set to enter Phase 1a/1b trials. As of December 31, 2020, the company reported approximately $123.3 million in cash and anticipates a net cash burn of $70-75 million in 2021, extending its cash runway to mid-2022.
Arbutus Biopharma Corporation (Nasdaq: ABUS) is participating in the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The virtual fireside chat will feature key executives, including President and CEO William Collier and Chief Scientific Officer Dr. Michael Sofia. The chat will be accessible via the company's website starting at 6:00 am EST on January 11, 2021. Arbutus focuses on developing treatments for chronic hepatitis B virus (HBV) and coronaviruses like COVID-19, with multiple drug candidates in progress.
Arbutus Biopharma (Nasdaq: ABUS) reported new clinical data from its Phase 1a/1b trial of AB-729, demonstrating significant safety and efficacy in treating chronic hepatitis B virus (HBV). The trial showed comparable declines in mean HBsAg levels with 60 mg doses administered every 4 weeks (–1.44 log10) and every 8 weeks (–1.37 log10, N=6). No serious adverse events were reported, reinforcing the drug's tolerability. The company aims to advance AB-729 into Phase 2a trials in 2021.
Arbutus Biopharma Corporation (Nasdaq: ABUS) released updated clinical data from its Phase 1a/1b trial of AB-729, an RNA interference therapeutic for chronic hepatitis B. The data showed significant declines in HBsAg with repeat 60 mg doses every 4 weeks, achieving a mean decline of -1.71 log10 IU/mL at week 20. A single 90 mg dose in HBV DNA positive subjects also resulted in meaningful reductions in HBsAg and HBV DNA. The company plans to advance AB-729 into Phase 2 combination studies, exploring less frequent dosing options. The product was reported to be safe and well tolerated.
Arbutus Biopharma Corporation (Nasdaq: ABUS) presented updated clinical data from its Phase 1a/1b trial of AB-729, a promising treatment for chronic hepatitis B infection. Key findings include a significant decline in HBsAg concentrations with repeat dosing of 60 mg every 4 weeks, showing further decline beyond week 12, with no plateau observed. AB-729 was generally safe and well tolerated, with expected decreases in HBV RNA and HBcrAg. A conference call is scheduled for November 16, 2020, to discuss these encouraging results further.